This is not just another tool to image cancer. The probe is a two-for-one: detect cancer and distinguish one type from another. Together, they develop a cancer fingerprint.
Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers at Michigan Technological University hope to reduce that timeframe down to minutes.
A collaborative team of chemists and engineers from Michigan Tech lays the groundwork for this vision in two new papers. In the Royal Society of Chemistry’s journal Chemical Communication (DOI: 10.1039/c7cc09809j), the team explains the basic science behind multicolor probes that enable targeting of a cancer-relevant fructose transporter, delving into the image-based detection of cancer cells. In the journal Biosensors (DOI: 10.3390/bios8020039), the team addresses applications for breast cancer detection and differentiating nonmalignant, pre-malignant and malignant cancer cells.
GLUT5 transports fructose and cancer loves sugar
Two Michigan Tech researchers collaborated on the studies. Marina Tanasova, assistant professor of chemistry, and Smitha Rao, assistant professor of biomedical engineering, turned a 10-minute office meeting into a two-year collaboration built on a tiny fluorescent probe that seeks out the fructose transporter named GLUT5.
Cells need carbohydrates; facilitative glucose transporters (GLUTs) bring nutrients in and out of cells. When metabolic swings kick in—say, from cancer development—the overall make-up of GLUTs change so that more or less GLUTs are active. Fructose transporters like GLUT5 are of particular interest because of the direct connection between fructose uptake and cancer development, which also changes as cancer progresses and becomes malignant.
In their Chemical Communications paper, Tanasova and Rao’s team report on the design and validation of the fluorescent probes, called ManCous, to observe GLUT5 activity in a cell. They document the multicolored fluorescence that distinguishes GLUT5-rich cells from those deficient in GLUT5. The follow up Biosensors paper provides a proof-of-principle use of these probes as tools to assess and compare GLUT5 and metabolic activity of different cell types, including normal cells and different cancer subtypes.
“We came closer to a basic screening of cells’ GLUT composition—one that both detects cancer and distinguishes type,” Tanasova says, adding that while the concept is elegant, developing the technology is not easy. “From basic science to application, there is a lot of transformation that has to happen.”
Engineering better cancer detection takes collaboration
By better understanding the science behind sugar transporters, the team is more equipped to build technology that captures an accurate and precise GLUT fingerprint of cancerous cells.
“This probe is like a Swiss army knife,” Rao says, explaining that cancer detection is not the only use for the probe. “The more we learn about cancer through these probes, the more opportunities we have to apply them—which means more chances to treat different cancers, hopefully cure them, and at least prevent their spread and maximize drug delivery.”
What makes the probe so versatile is its ability to not only seek out and highlight cancer cells, but also to reveal the metabolic nuances of different stages of cancer development. While cancer generally gobbles up fructose, the GLUT5 and metabolic activity of nonmalignant, pre-malignant and malignant breast cancer cells do vary, which is what Rao, Tanasova and their team explored in the Biosensors paper. They found that ManCou probes allow for parallel analysis and quantification of GLUT5 and metabolic activity of cells just after a 10-minute incubation period. The notable differences in fluorescence intensity observed between normal cells and cancer cells, as well as different cancer types, provide important points of differentiation between different cell types and make these probes promising tools for cancer detection and diagnostics.
The Latest on: Cancer fingerprint
via Google News
The Latest on: Cancer fingerprint
- Blood test to spot pancreatic cancer: Pioneering check-up that can give early diagnosis of the disease could be available within monthson July 5, 2021 at 5:57 pm
The first blood test for early diagnosis of the hard-to-spot disease, it could be available within months. Pancreatic cancer has the lowest survival rate of the common cancers.
- MasSpec Pen Shows Promise in Pancreatic Cancer Surgeryon July 5, 2021 at 12:39 pm
A diagnostic tool called the MasSpec Pen has been tested for the first time in pancreatic cancer patients during surgery. The device is shown to accurately identify tissues and surgical margins ...
- Prostate cancer drugs could help treat Covid-19 patientson July 1, 2021 at 7:57 am
The scientists focused on one of the proteins the virus uses to enter lung cells - TMPRSS2. Reducing levels of this protein could be a treatment optio..
- Insight: How blood tests are transforming cancer treatmenton June 30, 2021 at 6:52 am
A test that uses tumour DNA from the blood of patients with cancer, to predict if the disease will return after surgery, was developed by the TRACERx team led by UCL’s Professor Charles Swanton. Here, ...
- Who Needs Nipples Anyway? The Impacts of Breast Cancer Surgeryon June 28, 2021 at 11:00 am
Many women with breast cancer choose to undergo reconstruction after mastectomy. Of those women, some opt for nipple sparing surgeries while others do not. “Those who choose to save their nipples are ...
- How blood tests are transforming cancer treatmenton June 28, 2021 at 8:30 am
Four years ago, researchers in the CRUK TRACERx team at the Crick and UCL, alongside an industry-collaborator Natera, developed a personalized test that uses circulating fragments of tumor DNA (ctDNA) ...
- bladder canceron June 27, 2021 at 12:16 pm
One paper, which was published in Cancer Cytopathology, links the protein to pancreatic cancer. The other, published in the American Journal of Clinical Pathology, provides a potentially easier way to ...
- NHS trials 'holy grail' blood test that can spot 50 kinds of cancer: Ground-breaking check that can accurately detect two thirds of deadly cancers early in healthy people could ...on June 24, 2021 at 4:26 pm
The Galleri test, described as the 'holy grail' for cancer, detects the disease early in healthy people and NHS officials believe it has the potential to save thousands of lives every year.
- Deleted COVID-19 genetic fingerprints show it's still possible to dig for lab leak evidenceon June 24, 2021 at 2:32 pm
By 'deeply probing' data digitally archived outside China – from grant reports to reviews of scientific papers –more clues may be found.
via Bing News